X4 Pharmaceuticals’ (XFOR) “Buy” Rating Reaffirmed at HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $1.50 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 172.73% from the stock’s previous close.

Separately, Stifel Nicolaus cut their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Trading Down 10.8 %

Shares of XFOR opened at $0.55 on Friday. The firm’s fifty day moving average is $0.59 and its two-hundred day moving average is $0.60. The stock has a market cap of $93.80 million, a PE ratio of -6.11 and a beta of 0.12. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60.

Insider Activity at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 202,663 shares of company stock valued at $91,198. 1.62% of the stock is owned by company insiders.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC increased its holdings in X4 Pharmaceuticals by 1,080.3% in the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after purchasing an additional 388,115 shares during the last quarter. SG Americas Securities LLC acquired a new position in X4 Pharmaceuticals during the 3rd quarter worth about $37,000. GSA Capital Partners LLP purchased a new position in X4 Pharmaceuticals during the 3rd quarter valued at about $340,000. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals in the 3rd quarter valued at about $30,000. Finally, Point72 Asset Management L.P. increased its stake in X4 Pharmaceuticals by 15.1% during the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after purchasing an additional 81,968 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.